Securities Registration: Employee Benefit Plan (s-8)
March 09 2021 - 1:37PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on March 9, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
MOSAIC IMMUNOENGINEERING INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
84-1070278
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
2020 Omnibus Incentive Plan
(Full title of Plan)
1537 South Novato Blvd, #5
Novato, California 94947
Telephone: (657) 208-0890
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
Harvard Business Services, Inc.
16192 Coastal Hwy., Lewes, Delaware 19958
Telephone: (855) 336-5998
(Name, address, including zip code, and
telephone number, including area code, of agent for service)
Copies of all communications, including
communications sent to the agent for service, to:
Dean M. Colucci
Kelly A. Dabek
Duane Morris LLP
1540 Broadway
New York, NY 10036-4086
Telephone: (973) 424-2020
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer:
|
|
☐
|
|
Accelerated filer:
|
|
☐
|
Non-accelerated filer:
|
|
☒
|
|
Smaller reporting company:
|
|
☒
|
|
|
|
|
Emerging growth company:
|
|
☐
|
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act
CALCULATION OF REGISTRATION FEE
Title of securities to be registered
|
|
Amount to be
registered (1)
|
|
Proposed
maximum
offering price
per share
|
|
Proposed
maximum
aggregate
offering price
|
|
Amount of
registration
fee
|
Common Stock, par value $0.0001 per share
|
|
802,785
|
|
$4.00(2)
|
|
$3,211,140(2)
|
|
$350.34
|
|
(1)
|
Pursuant to Rule 416(a), under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional shares of the common stock, par value $0.00001 per share (“Common Stock”), of Mosaic ImmunoEngineering Inc. (the “Registrant”) that may be offered or issued by reason of certain corporate transactions or events, including any stock splits, stock dividends, recapitalization or any other similar transactions.
|
(2)
|
Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) and (h) under the Securities Act based on the average of the high and low prices of the shares of Common Stock, as reported by the OTC Markets on March 4, 2021.
|
|
|
|
|
|
|
|
|
|
|
PART I
INFORMATION REQUIRED IN THE SECTION 10(a)
PROSPECTUS
The information specified in Item 1
and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration
Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities
Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part
I of Form S-8 will be delivered to the participants in the respective plans. Such documents are not required to be, and
are not, filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement
or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT
In this Registration Statement, Mosaic
ImmunoEngineering Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”
|
Item 3.
|
Incorporation of Documents by Reference.
|
The following documents filed with the
Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated into
this Registration Statement by reference:
|
(a)
|
The Registrant's transition report on Form 10-K for the seven months ended December 31, 2020 filed with the Commission on March 2, 2021 pursuant to Section 13(a) or 15(d) of the Exchange Act; and
|
|
(b)
|
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, but prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary in such filing, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise be included in or deemed to be a part of, this Registration Statement.
|
For purposes of
this Registration Statement, any document or any statement contained in a document incorporated or deemed to be incorporated herein
by reference shall be deemed to be modified or superseded to the extent that a subsequently filed document or a statement contained
herein or in any other subsequently filed document that also is or is deemed to be incorporated herein by reference modifies or
supersedes such document or such statement in such document. Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this Registration Statement. Subject to the foregoing, all information in
this Registration Statement is so qualified in its entirety by the information appearing in the documents incorporated herein by
reference.
|
Item 4.
|
Description of Securities.
|
Description Of Our Common Stock
We are authorized to issue up to 100,000,000
shares of common stock, par value $0.00001 per share (“Common Stock”). As of March 4, 2021, we had 7,228,093 shares
of Common Stock issued and outstanding.
Except as provided by law or in a preferred
stock designation, holders of Common Stock are entitled to one vote for each share held of record on all matters submitted to a
vote of the stockholders, have the exclusive right to vote for the election of directors and do not have cumulative voting rights.
Except as otherwise required by law, holders
of Common Stock are not entitled to vote on any amendment to our Amended and Restated Certificate of Incorporation (including any
certificate of designations relating to any series of preferred stock) that relates solely to the terms of any outstanding series
of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or
more other such series, to vote thereon pursuant to our Amended and Restated Certificate (including any certificate of designations
relating to any series of preferred stock) or pursuant to the Delaware General Corporation Law (the “DGCL”). Subject
to prior rights and preferences that may be applicable to any outstanding shares or series of preferred stock, holders of Common
Stock are entitled to receive ratably in proportion to the shares of Common Stock held by them such dividends (payable in cash,
stock or otherwise), if any, as may be declared from time to time by our board of directors out of funds legally available for
dividend payments. All outstanding shares of Common Stock are fully paid and non-assessable.
The holders of Common Stock have no preferences
or rights of conversion, exchange, pre-emption or other subscription rights.
There are no redemption or sinking fund
provisions applicable to Common Stock.
In the event of any voluntary or involuntary
liquidation, dissolution or winding-up of our affairs, holders of Common Stock will be entitled to share ratably in our assets
in proportion to the shares of Common Stock held by them that are remaining after payment or provision for payment of all of our
debts and obligations and after distribution in full of preferential amounts to be distributed to holders of outstanding shares
of preferred stock, if any.
Among other things, our Amended and Restated
Certificate of Incorporation provides that, at any time after the first date on which our Common Stock is listed or quoted on a
national securities exchange (the “Trigger Date”):
|
·
|
any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing in lieu of a meeting of such stockholders, subject to the rights of the holders of any series of preferred stock with respect to such series (prior to such time, such actions may be taken without a meeting by written consent of holders of Common Stock having not less than the minimum number of votes that would be necessary to authorize such action at a meeting);
|
|
·
|
all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, or by a sole remaining director and shall not be filled by the stockholders (prior to such time, vacancies may also be filled by the affirmative vote of the holders of a majority of our then outstanding Common Stock);
|
|
·
|
our Amended and Restated Bylaws may only be amended by the affirmative vote of the holders of at least two-thirds of our then outstanding Common Stock (prior to such time, our bylaws may be amended by the affirmative vote of the holders of a majority of our then outstanding Common Stock);
|
|
·
|
special meetings of our stockholders may only be called by the board of directors pursuant to a resolution adopted by the affirmative vote of a majority of the board of directors (prior to such time, a special meeting may also be called at the request of stockholders holding a majority of the outstanding shares of Common Stock);
|
|
·
|
our director may be removed only for cause by the affirmative vote of the holders of at least 75% of the voting power of our then outstanding shares of Common Stock entitled to vote generally for the election of directors (prior to such time, any director may be removed at any time, either for or without cause, upon the affirmative vote of the holders of a majority of the voting power of our then outstanding shares of Common Stock entitled to vote generally for the election of directors); and
|
|
·
|
our board of directors can be divided into three classes of directors, with each class as nearly equal in number as possible, serving staggered three year terms, other than directors which may be elected by holders of preferred stock, if any (prior to such time, the directors shall consist of a single class with the initial term of office to expire at the first annual meeting of stockholders to occur following the Trigger Date). This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it could have the effect of increasing the length of time necessary to change the composition of a majority of the board of directors. In general, at least two annual meetings of stockholders will be necessary for stockholders to effect a change in a majority of the members of the board of directors.
|
|
Item 5.
|
Interests of Named Experts and Counsel.
|
Not applicable.
|
Item 6.
|
Indemnification of Directors and Officers.
|
Section 102 of the General Corporation
Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation
or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty
of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment
of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our
amended and restated certificate of incorporation provides that no director of the Registrant shall be personally liable to it
or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing
such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation
of liability of directors for breaches of fiduciary duty.
Section 145 of the General Corporation
Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of
the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust
or other enterprise in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or
is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position,
if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the
corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that,
in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim,
issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent
that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all
of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court
of Chancery or such other court shall deem proper.
Our amended and restated certificate of
incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or
she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as
a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture,
trust or other enterprise (all such persons being referred to as an "Indemnitee"), or by reason of any action alleged
to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom,
if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests,
and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
Our amended and restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an
action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was,
or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer,
partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other
enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection
with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she
reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that,
despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding
the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified
by us against all expenses (including attorneys' fees) actually and reasonably incurred in connection therewith. Expenses must
be advanced to an Indemnitee under certain circumstances.
We have entered into indemnification agreements
with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our
directors and officers for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director
or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries
or any other company or enterprise to which the person provides services at our request.
We maintain limited directors and officers’
liability insurance arising out of claims based on acts or omissions in their capacities as directors or officers.
|
Item 7.
|
Exemption from Registration Claimed.
|
Not applicable.
The following Exhibits are filed as part of this Registration
Statement:
* Filed herewith.
(a) The
undersigned Registrant hereby undertakes:
(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration Statement.
provided, however, that
paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d)
of the Exchange Act that are incorporated by reference in the Registration Statement.
(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.
(b) The
undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and,
where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act)
that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the Registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Novato, State of California, as of March 9, 2021.
|
|
|
|
|
Mosaic ImmunoEngineering Inc.
|
|
|
|
|
By:
|
|
/s/ Steven King
|
|
|
|
Steven King
|
|
|
|
President and Chief Executive Officer, and Director
|
POWER OF ATTORNEY
Know all persons by these presents, that
each person whose signature appears below constitutes and appoints Steven King and Paul Lytle, and each of them, as his/her true
and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him/her and in his/her name,
place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration
statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective
upon filing pursuant to Rule 462 promulgated under the Securities Act of 1933, as amended, and all post-effective amendments thereto,
and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act
and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could
do in person, hereby ratifying and confirming that each of said attorneys-in-fact and agents or any of them, or his or their substitute
or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates
indicated below.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Steven King.
Steven King
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
March 9, 2021
|
|
|
|
|
|
/s/ Paul Lytle
Paul Lytle
|
|
EVP, Chief Financial Officer and Director
(Principal Financial and Accounting Officer)
|
|
March 9, 2021
|
|
|
|
|
/s/ Nicole Steinmetz, Ph.D.
|
|
|
|
|
Nicole Steinmetz, Ph.D.
|
|
Acting Chief Scientific Officer and Director
|
|
March 9, 2021
|
|
|
|
|
|
/s/ Gloria Felcyn
Gloria Felcyn
|
|
Director
|
|
March 9, 2021
|
|
|
|
|
|
/s/ Carlton Johnson
Carlton Johnson
|
|
Director
|
|
March 9, 2021
|
|
|
|
|
|
/s/ Robert Garnick, Ph.D.
Robert Garnick, Ph.D.
|
|
Director
|
|
March 9, 2021
|
Mosaic ImmunoEngineering (PK) (USOTC:CPMV)
Historical Stock Chart
From May 2024 to Jun 2024
Mosaic ImmunoEngineering (PK) (USOTC:CPMV)
Historical Stock Chart
From Jun 2023 to Jun 2024